Glioblastoma (GBM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Glioblastoma
(GBM) Market Outlook
Thelansis’s “Glioblastoma (GBM)
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2025 To 2035” covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Glioblastoma (GBM) treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Glioblastoma
(GBM) Overview
Glioblastoma is the most common
primary malignant brain tumor in adults, defined strictly under current WHO
classification as an IDH-wildtype diffuse astrocytic glioma. It is
characterized by microvascular proliferation, intense therapeutic resistance, and
pseudopalisading necrosis. Driven by genomic alterations like EGFR
amplification and TERT promoter mutations, its management is heavily influenced
by MGMT promoter methylation status, which serves as a vital predictive
biomarker for alkylating chemotherapy response rather than an oncogenic driver.
Patients present with progressive headaches, seizures, and focal neurological
deficits. Diagnosis relies on contrast-enhanced brain MRI showing a
heterogeneously enhancing ring lesion, confirmed via histopathology. Standard
frontline care utilizes maximal safe resection followed by radiotherapy and
concurrent temozolomide, supplemented by tumor-treating fields. For recurrent
disease, the investigational frontier focuses on combination checkpoint
blockade, CAR-T platforms, dendritic cell vaccines, and oncolytic viruses
within clinical trials. Median survival remains constrained at fifteen months,
shifting dynamically based on age, performance status, and MGMT methylation.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by robust research, including:
- In-depth interviews with leading KOLs
and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based
automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2025–2035)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g.,
drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the most
promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment